TREM2 stabilizing antibodies

US11492402B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Verena BRAND · Munich, DE
• Dominik Feuerbach · Bad Hersfeld, DE
• Fabrizio Gasparini · Lausen, CH
• Nathalie George · Village-Neuf, FR
• Eveline Schaadt · Munich, DE
• Derya SHIMSHEK · Basel, CH
• Honnappa SRINIVAS · Brugg, CH
• Markus Waldhuber · Munich, DE
• Rainer WILCKEN · Basel, CH

Key dates

• Filing date: Oct 14, 2019
• Grant date: Nov 8, 2022
• Expiry date: Oct 14, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2750/14143
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides antibodies that bind to and stabilize human Triggering Receptor Expressed on Myeloid cells 2 (TREM2) protein and methods of using these antibodies.